

## **SCYNEXIS Inc**

### **CORTELLIS COMPANY DETAILED PIPELINE REPORT**

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 14-Dec-2014

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 11

    Phase 2 Clinical..... 12

    Phase 1 Clinical..... 20

    Discovery..... 27

    Suspended..... 38

[Return to Table of Contents](#)

## COMPANY OVERVIEW

Company Name	SCYNEXIS Inc
Parent Company Name	SCYNEXIS Inc
Website	http://www.scynexis.com/
Country	US
Number of Drugs in Active Development	7
Number of Inactive Drugs	8
Number of Patents as Owner	21
Number of Patents as Third Party	0
Number of Deals	23
Key Indications	Fungal infection, Trypanosoma cruzi infection, Trypanosoma brucei infection, Candida infection, Leishmania donovani infection, Hepatitis C virus infection, HIV infection, Aspergillus infection, Cryptococcus infection, Alzheimers disease, Amoeba infection, Asthma, Autoimmune disease, Dengue virus infection, Glomerulonephritis, Hepatitis B virus infection, Influenza virus infection, Insulin dependent diabetes, Ischemia, Keratitis, Meningitis, Pneumonia, Psoriasis, Reperfusion injury, Respiratory syncytial virus infection, Toxoplasma infection, Trichomonas
Key Target-based Actions	Peptidylprolyl isomerase inhibitor, 1,3 beta glucan synthase inhibitor, Calcineurin inhibitor, Peptidyl-prolyl cis-trans isomerase D inhibitor, IL-2 antagonist, Interleukin-29 ligand
Key Technologies	Small molecule therapeutic, Oral formulation, Biological therapeutic, Capsule formulation, Intravenous formulation, Natural product, Peptide, Assay, Chemical isolation, Fermentation synthesis, Stereochemical synthesis

## COMPANY PROFILE

### SUMMARY

SCYNEXIS (formerly SCYNEXIS Chemistry & Automation) is a chemistry- focused drug discovery company. Formed in 2000 as an independent spin-off of Aventis CropScience, SCYNEXIS utilizes its proprietary MEDCHEM-FACTORY to optimize lead molecules for candidate selection and deliver drug pipeline solutions to pharmaceutical partners from early discovery to phase II.

### COMPANY LOCATION

In December 2009, the company's process chemistry, analytical and manufacturing facilities were found to be in full compliance with cGMP manufacturing and analytical regulations following an FDA inspection.

### LICENSING AGREEMENTS

In May 2009, SCYNEXIS granted Medicines for Malaria Venture (MMV) access to its HEOS drug discovery platform.

In December 2008, SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi) extended their research alliance for an added three years. In November 2007, SCYNEXIS and DNDi established a drug research alliance to discover therapies for sleeping sickness.

In December 2006, SCYNEXIS Chemistry & Automation and Merck & Co formed a multi-year research collaboration to discover and develop new cancer drugs. SCYNEXIS would produce highly-targeted compound libraries and use rapid lead optimization techniques to select drug candidates. In October 2009, SCYNEXIS received a payment for a preclinical milestone.

By December 2005, SCYNEXIS and Merial were collaborating on the research of novel compounds for animal health needs. In November 2009, SCYNEXIS received a milestone payment from Merial in its multi-year research collaboration.

[Return to Table of Contents](#)



In October 2005, SCYNEXIS agreed to provide medicinal and analytical chemistry services for Teijin Pharma's drug development programs.

In April 2004, Norak Biosciences Inc and SCYNEXIS entered into a R&D collaboration. Norak transferred certain active compounds and chemical structures from its Transfluor screening program against novel desensitization targets to SCYNEXIS. Norak was to gain access to a SCYNEXIS research unit, which included medicinal chemistry technology and expertise. Norak was to receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services.

In November 2002, SCYNEXIS entered into a research collaboration with F Hoffmann-La Roche Ltd to discover and develop novel compounds for the CNS, and metabolic diseases. The transaction would include access by Roche to the SCYNEXIS MEDCHEM-FACTORY technology and HEOS Hit Explorer Operating System software, thus accelerating the identification of novel leads against Roche's drug targets by producing large, focused, high-purity compound libraries and then utilizing rapid lead optimization to identify clinical candidates. Specific financial terms were not disclosed. However, Roche was to receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services. In September 2003, this collaboration was extended.

In June 2002, SCYNEXIS entered into a multiyear research collaboration with Merck & Co Inc to discover and develop novel anti-infective compounds. Utilizing its proprietary MEDCHEM-FACTORY technology, SCYNEXIS was to accelerate the identification of novel drugs against Merck's screening targets by producing large, highly targeted, high-purity compound libraries. Merck was to receive exclusive worldwide rights to products developed through the collaboration. SCYNEXIS was to receive milestone payments and royalties on sales. In July 2003, this research collaboration was expanded. In January 2007, SCYNEXIS received a \$1 million payment from Merck & Co for meeting preclinical milestones under the companies' 2002 collaboration to develop antifungal agents. In December 2009, SCYNEXIS achieved a third milestone in its collaboration with Merck & Co to develop antifungals. The milestone was triggered by the initiation of clinical development for a compound generated under the collaboration. Under the terms of the original agreement, SCYNEXIS would receive milestones and double-digit percentage royalties.

In December 2001, Plexxikon Inc signed an agreement with SCYNEXIS, under the terms of which Plexxikon will access SCYNEXIS' proprietary MEDCHEM-FACTORY technology in order to accelerate its chemistry programs.

In February 2001, SCYNEXIS formed an alliance with two additional specialized research companies, Piedmont Research Center and Biotechnics Inc, to enhance its ability to quickly identify and bring forward the development of promising drug candidates.

## FINANCIAL

By June 2014, SCYNEXIS had repayed a \$15 million credit facility.

In May 2014, the company priced its IPO of 6,200,000 shares of its common stock at \$10 per share. The underwriters were also granted a 30-day over-allotment option to purchase up to an additional 930,000 shares of common stock. In June 2014, the company raised net proceeds of \$40 million from the completed offering.

In March 2014, the company announced a initial public offering of 4,230,800 shares of its common stock priced between \$12.00 and \$14.00 per share. The underwriters were to be granted a 30-day option to purchase additional 634,620 shares of the common stock. At that time, the company filed an application to list the shares under the ticker symbol "SCYX" on the NASDAQ Global Market. In May 2014, the company's shares began trading on the NASDAQ Global Market.

In March 2008, SCYNEXIS completed a \$13.5 million Series C2 financing.


[Return to Table of Contents](#)

# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	7	6	13
Inflammatory disease	0	5	5
Gastrointestinal disease	0	4	4
Endocrine disease	0	1	1
Metabolic disorder	0	1	1
Cardiovascular disease	0	1	1
Musculoskeletal disease	0	1	1
Ocular disease	0	1	1
Injury	0	1	1
Neurological disease	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	5
Suspended	1
Discontinued	1
No Development Reported	7

[Return to Table of Contents](#)



## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	3	0	0	0	3
Technology - Other Proprietary	5	0	0	0	5
Drug - Early Research/Development	1	0	2	0	3
Drug - Discovery/Design	3	0	1	0	4
Drug - Funding	1	0	0	0	1
Technology - Target Validation	0	1	0	1	1
Drug - Development Services	6	0	0	0	6

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	1	4
Inflammatory disease	0	3
Gastrointestinal disease	0	3

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	2
Phase 1	0	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Endocrine disease	1	0	1

[Return to Table of Contents](#)



Gastrointestinal disease	13	0	13
Genitourinary disease	1	0	1
Degeneration	1	0	1
Immune disorder	1	0	1
Ocular disease	2	0	2
Metabolic disorder	1	0	1
Neurological disease	2	0	2
Respiratory disease	3	0	3
Infectious disease	20	0	20
Injury	1	0	1
Inflammatory disease	16	0	16
Dermatological disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### SCY-078

#### SCY-078 SNAPSHOT

<b>Drug Name</b>	SCY-078
<b>Key Synonyms</b>	
<b>Originator Company</b>	Merck & Co Inc
<b>Active Companies</b>	R-Pharm;SCYNEXIS Inc
<b>Inactive Companies</b>	Merck & Co Inc
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Candida infection;Fungal infection
<b>Target-based Actions</b>	1,3 beta glucan synthase inhibitor
<b>Other Actions</b>	Fungicide;Glucan synthesis inhibitor
<b>Technologies</b>	Natural product;Oral formulation;Small molecule therapeutic
<b>Last Change Date</b>	14-Nov-2014

#### SCY-078 DEVELOPMENT PROFILE

##### SUMMARY

SCYNEXIS, in collaboration with R-Pharm, is developing SCY-078 (formerly MK-3118; structure shown), an orally active inhibitor of glucan synthesis, the lead from analogs of enfumafungin, a triterpene glycoside derived from a culture belonging to the genus *Hormonema*, as beta-(1,3) D glucan synthase inhibitors for the potential oral treatment of fungal infections, including invasive candidiasis,. In September 2014, a phase II trial was initiated in the US in hospitalized nonneutropenic adults for the treatment of invasive candidiasis. The trial was expected to complete in November 2015.

Merck & Co was developing the drug in collaboration with SCYNEXIS for the potential treatment of fungal infections,. However in May 2013, following a review and prioritization of Merck's infectious disease pipeline, rights were returned to SCYNEXIS.

SCYNEXIS is also investigating intravenous formulation of SCY-078 for the potential oral treatment of fungal infections.

##### REGULATORY INFORMATION US

In February 2014, FDA designated oral SCY-078 as a Qualified Infectious Disease Product for indications of invasive candidiasis, including candidemia and aspergillosis.

[Return to Table of Contents](#)



## SCY-078 DEVELOPMENT STATUS

### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
SCYNEXIS Inc	Candida infection	US	Phase 2 Clinical	27-Sep-2014
SCYNEXIS Inc	Fungal infection	US	Phase 1 Clinical	31-Oct-2009
R-Pharm	Fungal infection	Russian Federation	Discovery	10-Sep-2013
Merck & Co Inc	Fungal infection	US	Discontinued	29-May-2013


### SCY-078 CHEMICAL STRUCTURES


CAS Registry Number:	Confidence Level:
	4
<p>The chemical structure of MK-3118 (SCY-078) is a complex polycyclic molecule. It features a central steroid-like core with multiple fused rings. A pyridine ring is attached to the core via a triazole linker. Another side chain includes a hydroxyl group and a carboxylic acid group. A tert-butyl group is also present on the structure.</p>	
Name	Type
MK-3118	Research Code
SCY-078	Research Code

CAS Registry Number:	Confidence Level:
	3
<p>The chemical structure of enfumafungin is a complex polycyclic molecule. It features a central steroid-like core with multiple fused rings. It has several hydroxyl groups and a carboxylic acid group. A side chain includes a hydroxyl group and a carboxylic acid group. A tert-butyl group is also present on the structure.</p>	
Name	Type
enfumafungin	


[Return to Table of Contents](#)


CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	4
	

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	4
	

## SCY-078 DRUG NAMES

Names	Type
SCY-078	Research Code
MK-3118	Research Code
antifungal compounds (1,3 beta glucan synthase inhibitors), Merck/SCYNEXIS	
enfumafungin (antifungal), Merck & Co	
enfumafungin analogs (antifungal), Merck & Co/SCYNEXIS	
enfumafungin	
triterpene glycoside analogs (antifungal), Merck & Co	

[Return to Table of Contents](#)

## SCY-078 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Candida infection											
0	0	0	0	1	1	0	0	0	0	1	1
Fungal infection											
0	0	0	0	0	0	0	1	0	0	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	2	0	0	1	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

SCY-078 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
SCYNEXIS Inc	2	0	0	0	2
R-Pharm	0	0	1	0	1
Merck & Co Inc	0	0	1	0	1

[Return to Table of Contents](#)



Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Discovery/Design	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
SCYNEXIS Inc	2	0	2
Merck & Co Inc	2	0	2

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1
Process (Intermediate)	1

[Return to Table of Contents](#)

## SCYX-7158

### SCYX-7158 SNAPSHOT

<b>Drug Name</b>	SCYX-7158
<b>Key Synonyms</b>	
<b>Originator Company</b>	SCYNEXIS Inc
<b>Active Companies</b>	SCYNEXIS Inc;Drugs for Neglected Diseases Initiative;Anacor Pharmaceuticals Inc;Pace University
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Trypanosoma cruzi infection;Trypanosoma brucei infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic;Unspecified drug target
<b>Technologies</b>	Oral formulation;Small molecule therapeutic
<b>Last Change Date</b>	23-May-2014

### SCYX-7158 DEVELOPMENT PROFILE

#### SUMMARY

SCYNEXIS, Anacor Pharmaceuticals, Pace University and the Drugs for Neglected Diseases Initiative (DNDi) are developing SCYX-7158 (AN-5568), the lead in an oxaborole series, including AN-2920, AN-3520 and SCYX-6759 (AN-4169), for the potential oral treatment of human African trypanosomiasis (HAT, sleeping sickness, Trypanosoma brucei infection) and Chagas disease (Trypanosoma cruzi infection). In February 2012, DNDi initiated a phase I trial of SCYX-7158. In January 2014, the drug was listed as being in phase I development. In December 2013, data from phase I trial was expected in the first half of 2014 and a phase II/III trial was expected to be initiated in the second half of 2014. In March 2011, Anacor was seeking to outlicense the program.

### SCYX-7158 DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Drugs for Neglected Diseases Initiative	Trypanosoma brucei infection	France	Phase 1 Clinical	15-Feb-2012
Anacor Pharmaceuticals Inc	Trypanosoma brucei infection	US	Discovery	11-Dec-2008
Anacor Pharmaceuticals Inc	Trypanosoma cruzi infection	US	Discovery	31-Dec-2007
Drugs for Neglected Diseases Initiative	Trypanosoma cruzi infection	US	Discovery	31-Dec-2007
Pace University	Trypanosoma brucei infection	US	Discovery	11-Dec-2008

[Return to Table of Contents](#)


Company	Indication	Country	Development Status	Date
SCYNEXIS Inc	Trypanosoma brucei infection	US	Discovery	11-Dec-2008
SCYNEXIS Inc	Trypanosoma cruzi infection	US	Discovery	15-Aug-2010


### SCYX-7158 CHEMICAL STRUCTURES


CAS Registry Number:	Confidence Level:
	4
	
Name	Type
SCYX-7158	Research Code

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
AN-4169	Research Code
SCYX-6759	Research Code

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	3
	

CAS Registry Number:	Confidence Level:
	3
	

[Return to Table of Contents](#)

## SCYX-7158 DRUG NAMES

Names	Type
AN-5568	Research Code
trypanocidal compounds, SCYNEXIS/DNDi/Pace University/Anacor Pharmaceuticals	
SCYX-7158	Research Code
AN-3520	Research Code
SCYX-6759	Research Code
boron based antiparasitic compounds (chagas disease), Anacor Pharmaceuticals/DNDi	
AN-4169	Research Code
AN-2920	Research Code
oxaborole series (human African trypanosomiasis), SCYNEXIS/DNDi/Pace University/Anacor Pharmaceuticals	

## SCYX-7158 CLINICAL TRIALS

### Total Trials by Phase and Status


Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

SCYX-7158 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



[Return to Table of Contents](#)




## Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drugs for Neglected Diseases Initiative	10	0	2	0	12
SCYNEXIS Inc	2	0	0	0	2
German Government	0	0	1	0	1
Swiss Agency for Development and Cooperation	0	0	1	0	1
Sanofi	0	0	1	0	1
Penn Pharmaceuticals Ltd	0	0	1	0	1
Pace University	0	0	1	0	1
Advinus Therapeutics Ltd	0	0	1	0	1
Netherlands Government	0	0	1	0	1
Bill & Melinda Gates Foundation	0	0	1	0	1
Médecins Sans Frontières	0	0	1	0	1
Department for International Development	0	0	1	0	1
Spanish Government	0	0	1	0	1
Anacor Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	7	0	7
Drug - Development/Commercialization License	5	0	5
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

## SCY-078 (intravenous, antifungal), SCYNEXIS

### SCY-078 (intravenous, antifungal), SCYNEXIS SNAPSHOT

Drug Name	SCY-078 (intravenous, antifungal), SCYNEXIS
Key Synonyms	
Originator Company	SCYNEXIS Inc
Active Companies	SCYNEXIS Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Fungal infection
Target-based Actions	1,3 beta glucan synthase inhibitor
Other Actions	Fungicide;Glucan synthesis inhibitor
Technologies	Natural product;Intravenous formulation;Biological therapeutic
Last Change Date	23-Oct-2014

### SCY-078 (intravenous, antifungal), SCYNEXIS DEVELOPMENT PROFILE

#### SUMMARY

SCYNEXIS is investigating an intravenous formulation of SCY-078 (formerly MK-3118), an active inhibitor of glucan synthesis the lead from analogs of enfumafungin, a triterpene glycoside derived from a culture belonging to the genus *Hormonema*, as beta-(1,3) D glucan synthase inhibitors, for the potential treatment of fungal infections caused by *Candida* and *Aspergillus* species,. In October 2014, the company planned to begin clinical studies in 2015.

SCYNEXIS is also developing an oral formulation of SCY-078 for the potential treatment of fungal infections.


### SCY-078 (intravenous, antifungal), SCYNEXIS DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SCYNEXIS Inc	Fungal infection	US	Discovery	05-Jun-2013

### SCY-078 (intravenous, antifungal), SCYNEXIS CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
MK-3118	Research Code
SCY-078	Research Code

### SCY-078 (intravenous, antifungal), SCYNEXIS DRUG NAMES

Names	Type
SCY-078	Research Code
MK-3118	Research Code
SCY-078 (intravenous, antifungal), SCYNEXIS	

[Return to Table of Contents](#)

## Oxachagas

### Oxachagas SNAPSHOT

<b>Drug Name</b>	Oxachagas
<b>Key Synonyms</b>	
<b>Originator Company</b>	Drugs for Neglected Diseases Initiative
<b>Active Companies</b>	Drugs for Neglected Diseases Initiative;Murdoch University;SCYNEXIS Inc;University of Antwerp;Anacor Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Trypanosoma cruzi infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target;Antiparasitic
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	03-Sep-2014

### Oxachagas DEVELOPMENT PROFILE

#### SUMMARY

Drugs for Neglected Diseases Initiative in collaboration with Anacor Pharmaceuticals, SCYNEXIS, Murdoch University and University of Antwerp, is investigating Oxachagas, a program of oxaboroles, for the potential treatment of Chagas disease. By August 2014, research was underway.

### Oxachagas DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Anacor Pharmaceuticals Inc	Trypanosoma cruzi infection	US	Discovery	31-Aug-2014
Drugs for Neglected Diseases Initiative	Trypanosoma cruzi infection	Switzerland	Discovery	31-Aug-2014
Murdoch University	Trypanosoma cruzi infection	Australia	Discovery	31-Aug-2014
SCYNEXIS Inc	Trypanosoma cruzi infection	US	Discovery	31-Aug-2014
University of Antwerp	Trypanosoma cruzi infection	Belgium	Discovery	31-Aug-2014

[Return to Table of Contents](#)




Oxachagas DRUG NAMES

Names	Type
oxaborole series (Chagas disease), DNDi/Anacor Pharmaceuticals/SCYNEXIS/Murdoch Uni/Uni of Antwerp	
Oxachagas	

Oxachagas DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals  
Total: 11


- Drugs for Neglected Diseases Initiative
- Anacor Pharmaceuticals Inc
- Department for International Development
- German Government
- Murdoch University
- Netherlands Government
- SCYNEXIS Inc
- Sandexis LLP
- Spanish Government
- Other

[Return to Table of Contents](#)

## Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drugs for Neglected Diseases Initiative	5	0	6	0	11
German Government	0	0	1	0	1
WuXi PharmaTech Co Ltd	1	0	0	0	1
Murdoch University	1	0	0	0	1
Anacor Pharmaceuticals Inc	1	0	0	0	1
Sandexis LLP	1	0	0	0	1
SCYNEXIS Inc	1	0	0	0	1
Swiss Agency for Development and Cooperation	0	0	1	0	1
University of Antwerp	1	0	0	0	1
Netherlands Government	0	0	1	0	1
Department for International Development	0	0	1	0	1
Spanish Government	0	0	1	0	1

## Deals by Type Chart



[Return to Table of Contents](#)

### Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	5	0	5
Drug - Development Services	2	0	2
Drug - Development/Commercialization License	2	0	2
Drug - Early Research/Development	1	0	1
Drug - Screening/Evaluation	1	0	1

[Return to Table of Contents](#)



## oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi

### oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi SNAPSHOT

<b>Drug Name</b>	oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi
<b>Key Synonyms</b>	
<b>Originator Company</b>	Anacor Pharmaceuticals Inc
<b>Active Companies</b>	London School of Hygiene and Tropical Medicine;SCYNEXIS Inc;Anacor Pharmaceuticals Inc;University of Antwerp;Drugs for Neglected Diseases Initiative
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Leishmania donovani infection;Trypanosoma cruzi infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic;Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	02-Sep-2014

### oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DEVELOPMENT PROFILE

#### SUMMARY

Anacor Pharmaceuticals, Drugs for Neglected Diseases initiative (DNDi) and its partners SCYNEXIS, University of Antwerp and The London School of Hygiene and Tropical Medicine (LSHTM), are investigating Oxaleish (DNDi-2035804), a lead from a series of oxaboroles, for the potential treatment of visceral leishmaniasis (VL) and Chagas disease, . In March 2011, the program was listed as being in research on Anacor's pipeline; in January 2014, this was still the case. In August 2014, preclinical efficacy, pharmacokinetics, and safety profiling of the lead compound was ongoing.

### oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Anacor Pharmaceuticals Inc	Leishmania donovani infection	US	Discovery	31-Dec-2007
Anacor Pharmaceuticals Inc	Trypanosoma cruzi infection	US	Discovery	31-Dec-2007
Drugs for Neglected Diseases Initiative	Leishmania donovani infection	Switzerland	Discovery	31-Dec-2007
Drugs for Neglected Diseases Initiative	Trypanosoma cruzi infection	Switzerland	Discovery	31-Dec-2007
London School of Hygiene and Tropical Medicine	Leishmania donovani infection	UK	Discovery	31-Aug-2014

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
SCYNEXIS Inc	Leishmania donovani infection	US	Discovery	31-Aug-2014
University of Antwerp	Leishmania donovani infection	Belgium	Discovery	31-Aug-2014


### oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DRUG NAMES

Names	Type
oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi	
Oxaleish	
DNDi-2035804	Research Code
boron based antiparasitic compounds (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi	

### oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DEALS AND PATENTS

#### DEALS

#### Deals by Parent Company Chart




[Return to Table of Contents](#)

## Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drugs for Neglected Diseases Initiative	2	0	5	0	7
Sandexis LLP	1	0	0	0	1
SCYNEXIS Inc	0	0	1	0	1
Anacor Pharmaceuticals Inc	1	0	0	0	1
Bill & Melinda Gates Foundation	0	0	1	0	1
University of Antwerp	1	0	0	0	1
University of London	1	0	0	0	1
WuXi PharmaTech Co Ltd	1	0	0	0	1

## Deals by Type Chart



[Return to Table of Contents](#)

### Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	3	0	3
Drug - Development Services	2	0	2
Drug - Development/Commercialization License	1	0	1
Drug - Funding	1	0	1

[Return to Table of Contents](#)

antifungal therapeutics, SCYNEXIS

antifungal therapeutics, SCYNEXIS SNAPSHOT

Drug Name	antifungal therapeutics, SCYNEXIS
Key Synonyms	
Originator Company	SCYNEXIS Inc
Active Companies	SCYNEXIS Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Fungal infection
Target-based Actions	
Other Actions	Unspecified drug target;Fungicide
Technologies	Small molecule therapeutic
Last Change Date	16-Oct-2014

antifungal therapeutics, SCYNEXIS DEVELOPMENT PROFILE

SUMMARY

SCYNEXIS is investigating therapeutics for the potential treatment of fungal infections. In October 2014, the program was listed as being in preclinical development.

antifungal therapeutics, SCYNEXIS DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SCYNEXIS Inc	Fungal infection	US	Discovery	14-Oct-2014

antifungal therapeutics, SCYNEXIS DRUG NAMES

Names	Type
antifungal therapeutics, SCYNEXIS	

[Return to Table of Contents](#)

## oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS

### oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS SNAPSHOT

<b>Drug Name</b>	oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS
<b>Key Synonyms</b>	
<b>Originator Company</b>	Drugs for Neglected Diseases Initiative
<b>Active Companies</b>	Anacor Pharmaceuticals Inc;Drugs for Neglected Diseases Initiative;Pace University;SCYNEXIS Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Suspended
<b>Active Indications</b>	Trypanosoma brucei infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic;Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	05-Sep-2014

### oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DEVELOPMENT PROFILE

#### SUMMARY

Drugs for Neglected Diseases initiative (DNDi), SCYNEXIS, Anacor and Pace University were investigating SCYX-1608210 and SCYX-1330682 as backup compounds of SCYX-7158, an oxaborole, for the potential treatment of human African trypanosomiasis (HAT),. In April 2007, development was ongoing ; in August 2012, the program was listed as being under preclinical development. In January 2014, the program was listed as being under research. However, by September 2014, further development of both compounds was suspended; due to limited resources, DNDi would focus on the development of SCYX-7158 and fexinidazole and would only re-open the program if SCYX-7158 did not prove to be successful in clinical trials.

### oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Anacor Pharmaceuticals Inc	Trypanosoma brucei infection	US	Suspended	03-Sep-2014
Drugs for Neglected Diseases Initiative	Trypanosoma brucei infection	Switzerland	Suspended	03-Sep-2014
Pace University	Trypanosoma brucei infection	US	Suspended	03-Sep-2014
SCYNEXIS Inc	Trypanosoma brucei infection	US	Suspended	03-Sep-2014

[Return to Table of Contents](#)




oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DRUG NAMES

Names	Type
oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS SCYX-1608210	Research Code
backup compounds of SCYX-7158 (HAT), DNDi/Anacor/Pace University/SCYNEXIS SCYX-1330682	Research Code

oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

## Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drugs for Neglected Diseases Initiative	4	0	4	0	8
Department for International Development	0	0	1	0	1
Médecins Sans Frontières	0	0	1	0	1
Anacor Pharmaceuticals Inc	1	0	0	0	1
SCYNEXIS Inc	1	0	0	0	1
WuXi PharmaTech Co Ltd	1	0	0	0	1
Pace University	1	0	0	0	1
Swiss Agency for Development and Cooperation	0	0	1	0	1
Spanish Government	0	0	1	0	1

## Deals by Type Chart



[Return to Table of Contents](#)



### Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	4	0	4
Drug - Development/Commercialization License	3	0	3
Drug - Development Services	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

